[1]
|
R. A. DeFronzo, R. C. Bonadonna and E. Ferrannini, “Pathogenesis of NIDDM: A Balanced Overview,” Diabetes Care, Vol. 15, No. 3, 1992, pp. 318-368.
doi:10.2337/diacare.15.3.318
|
[2]
|
WHO, “Diabetes Action Now: An Initiative of the World Health Organization and the International Diabetic Federation,” WHO, Geneva, IDF, Brussels, 2004, pp. 1-20.
|
[3]
|
P. Lenzo, “One Adult in Ten will Have Diabetes by 2030,” IDF Diabetes Atlas, Brussels, 2011.
|
[4]
|
G. Roglic, “Estimates of the Global and Regional Burden of Diabetes,” 4th Edition, IDF Diabetes Atlas, Brussels, 2012.
|
[5]
|
R. E. Lamb and B. J. Goldstein, “Modulating an Oxidative-Inflammatory Cascade: Potential New Treatment Strategy for Improving Glucose Metabolism, Insulin Resistance, and Vascular Function,” International Journal of Clinical Practice, Vol. 62, No. 7, 2008, pp. 1087-1095.
doi:10.1111/j.1742-1241.2008.01789.x
|
[6]
|
J. S. Johansen, A. K. Harris, D. J. Rychly and A. Ergul, “Oxidative Stress and the Use of Antioxidants in Diabetes: Linking Basic Science to Clinical Practice,” Cardiovascular Diabetology, Vol. 4, No. 1, 2005, p. 5.
doi:10.1186/1475-2840-4-5
|
[7]
|
T. Jaakko, “Reducing Coronary Heart Disease Associated with Type 2 Diabetes: Lifestyle Intervention and Treatment of Dyslipidaemia,” Diabetes Research and Clinical Practice, Vol. 61, Supplement 1, 2003, pp. S27-S34.
doi:10.1016/S0168-8227(03)00125-6
|
[8]
|
C. Rafael, “Type 2 Diabetes, Dyslipidemia, and Vascular Risk: Rationale and Evidence for Correcting the Lipid Imbalance,” American Heart Journal, Vol. 150, No. 5, 2005, pp. 859-870. doi:10.1016/j.ahj.2005.04.027
|
[9]
|
M. H. Davidson. “Statin/Fibrate Combination in Patients with Metabolic Syndrome or Diabetes: Evaluating the Risks of Pharmacokinetic Drug Interactions,” Expert Opinion on Drug Safety, Vol. 5, No. 1, 2006, pp. 145-156. doi:10.1517/14740338.5.1.145
|
[10]
|
M. P. Solano and R. B. Goldberg. “Lipid Management in Type 2 Diabetes,” Clinical Diabetes, Vol. 24, No. 1, 2006, pp. 27-32.
|
[11]
|
R. Balasubramanian, et al., “Assessment of the Efficacy and Tolerability of a Fixed Dose Combination of Atorvastatin 10 mg + Metformin SR 500 mg in Diabetic Dyslipidaemia in Adult Indian Patients,” Journal of the Indian Medical Association, Vol. 106, No. 7, 2008, pp. 464467.
|
[12]
|
S. M. Haffner, et al., “Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in NonDiabetic Subjects with and without Prior Myocardial Infarction,” The New England Journal of Medicine, Vol. 339, No. 4, 1998, pp. 229-234.
doi:10.1056/NEJM199807233390404
|
[13]
|
H. Miettinem, et al. and the FINMONICA Myocardial Infarction Register Study Group, “Impact of Diabetes on Mortality after the First Myocardial Infarction,” Diabetes Care, Vol. 21, No. 1, 1998, pp. 69-75.
doi:10.2337/diacare.21.1.69
|
[14]
|
J. W. Baynes and S. R. Thorpe, “Role of Oxidative Stress in Diabetic Complications: A New Perspective on an Old Paradigm,” Diabetes, Vol. 48, No. 1, 1999, pp. 1-9.
doi:10.2337/diabetes.48.1.1
|
[15]
|
J. W. Baynes, “Role of Oxidative Stress in Development of Complications in Diabetes,” Diabetes, Vol. 40, No. 4, 1991, pp. 405-412. doi:10.2337/diabetes.40.4.405
|
[16]
|
Z. A. Latif, A. Jain and M. M. Rahman, “Evaluation of Management, Control, Complications and Psychosocial Aspect of Diabetes in Bangladesh: DiabCare Bangladesh 2008,” Bangladesh Medical Research Council Bulletin, Vol. 37, No. 1, 2011, pp. 11-16.
|
[17]
|
S. Ghosh, A. Collier, M. Hair, I. Malik and T. Elhadd, “Metabolic Syndrome in Type 1 Diabetes,” International Journal of Diabetes Mellitus, Vol. 2, No. 1, 2010, pp. 38-42. doi:10.1016/j.ijdm.2009.10.005
|
[18]
|
K. Kasim, M. Amar, A. A. El Sadek and S. A. Gawad, “Peripheral Neuropathy in Type 2 Diabetic Patients Attending Diabetic Clinics in Al-Azhar University Hospitals, Egypt,” International Journal of Diabetes Mellitus, Vol. 2, No. 1, 2010, pp. 20-23. doi:10.1016/j.ijdm.2009.10.002
|
[19]
|
S. M. Kim, J. S. Lee, J. Lee, J. K. Na, J. H. Han, D. K. Yoon, S. H. Baik, D. S. Choi and K. M. Chi, “Prevalence of Diabetes and Impaired Fasting in Korea,” Diabetes Care, Vol. 29, No. 2, 2006, pp. 226-232.
doi:10.2337/diacare.29.02.06.dc05-0481
|
[20]
|
A. Bener, M. Zirie and A. Al-Rakabi, “Genetics, Obesity and Environmental Risk Factors Associated with Type 2 Diabetes,” Croatian Medical Journal, Vol. 46, No. 2, 2005, pp. 302-307.
|
[21]
|
A. Gupta, R. Gupta, M. Sarna, S. Rastogi, V. P. Gupta and K. Kothari, “Prevalence of Diabetes, Impaired Fasting Glucose and Insulin Resistance Syndrome in an Indian Population,” Diabetes Research and Clinical Practice, Vol. 61, No. , 2003, pp. 69-76.
doi:10.1016/S0168-8227(03)00085-8
|
[22]
|
M. G. Kibriya and H. Mahtab, “Micro-Vascular Complications in Type 2 Diabetes in Bangladesh: The Diabcare-Asia, Bangladesh Project,” Diabetes Research Clinical Practice, Vol. 50, Supplement 1, 2000, pp. 135-136.
|
[23]
|
H. Mahtab and M. G. Kibriya, “The Diabcare-Asia, Bangladesh Project: Management of Diabetes in Bangladesh,” Diabetes Research Clinical Practice, Vol. 50, Supplement 1, 2000, p. 55.
|
[24]
|
W. Patrick, E. H. M. Sullivan, G. Vahram, H. R. Wyatt and J. O. Hill, “Obesity, Inactivity, and the Prevalence of Diabetes and Diabetes Related Cardiovascular Co Morbidities in the US, 2000-2002,” Diabetes Care, Vol. Vol. 28, No. 7, 2005, pp. 1599-1603.
doi:10.2337/diacare.28.7.1599
|
[25]
|
S. G. Wannamethee and A. G. Shaper, “Weight Change and Duration of Overweight and Obesity in the Incidence of Type 2 Diabetes,” Diabetes Care, Vol. 22, No. 8, 1999, pp. 1266-1272. doi:10.2337/diacare.22.8.1266
|
[26]
|
A. K. Azad, M. A. Kabir, P. K. Roy, A. Raihan, M. T. Rahman and M. Hasan, “Diabetes Mellitus with MultiSystemic Complications,” Bangladesh Journal of Medicine, Vol. 10, 1999, pp. 53-55.
|
[27]
|
A. B. Anjuman, A. K. Azad, M. A. Alim and E. Saifuddin, “Nutritional Status of Diabetic Patients Attending to a District Level Diabetic Center,” The Journal of Teachers Association RMC, Vol. 17, No. 2, 2004, pp. 89-92.
|
[28]
|
H. Jorgensen, H. Nakayama, H. O. Raaschou and T. S. Olsen, “Stroke in Patients with Diabetes: The Copenhagen Stroke Study,” Vol. 25, No. 10, 1994, pp. 1977-1984.
doi:10.1161/01.STR.25.10.1977
|
[29]
|
D. M. Nathan, J. Lachin, P. A. Cleary and J. Y. Backlund, “Intensive Diabetes Therapy and Carotid Intima-Media Thickness in Type 1 Diabetes Mellitus,” NEJM, Vol. 348, No. 23, 2003, pp. 2294-303.
doi:10.1056/NEJMoa022314
|
[30]
|
H. Sone, S. Mizuno, Y. Ohashi, et al., “Prevention and Therapeutic Strategy of Metabolic Syndrome-Implications from the Interim Results of Japan Diabetes Complications Study (JDCS),” Nippon Rinsho, Vol. 62, No. 6, 2004, pp. 1150-1157.
|